References

1. Harris, N.L.; Jaffe, E.S.; Diebold, J.; Flandrin, G.; Muller-Hermelink, H.K.; Vardiman, J.; Lister, T.A.; Clara, D.; Bloomfield, C.D. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November, 1997. J. Clin. Oncol. 1999, 17 (12), 3835-3849.

2. Harris, N.H.; Jaffe, E.S.; Stein, H.; Banks, P.M.; Chan, 12. J.K.; Cleary, M.L.; Delsol, G.; De Wolf-Peeters, C.; Falini,

B.; Gatter, K.C. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84 (5), 1361-1392.

Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group. Br. J. Haematol. 1976, 33 (4), 451-458.

Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.G.; Gralnick, H.R.; Sultan, C.R. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). Ann. Intern. Med. 1985, 103, 460-462. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.G.; Gralnick, H.R.; Sultan, C.R. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985, 103, 620625.

Heim, S.; Mitelman, F. Cancer Cytogenetics, 2nd Ed.; Wiley-Liss: New York, 1995.

Byrd, J.C.; Dodge, R.K.; Carroll, A.; Baer, M.R.; Edwards,

C.; Stamberg, J.; Qumsiyeh, M.; Moore, J.O.; Mayer, R.J.; Davey, F.; Schiffer, C.A.; Bloomfield, C.D. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J. Clin. Oncol. 1999, 17 (12), 3767-3775.

Hiddemann, W.; Kern, W.; Schoch, C.; Fonatsch, C.; Heinecke, A.; Wormann, B.; Büchner, T. Management of acute myeloid leukemia in elderly patients. J. Clin. Oncol. 1999, 17 (11), 3569-3576.

Ferrant, A.; Labopin, M.; Frassoni, F.; Prentice, H.G.; Cahn, J.Y.; Blaise, D.; Reiffers, J.; Visani, G.; Sanz, M.A.; Boogaerts, M.A.; Löwenberg, B.; Gorin, N.C.; on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Karyo-type in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Blood 1997, 90 (8), 2391-2938. Leith, C.P.; Kopecky, K.J.; Godwin, J.; McConnell, T.; Slovak, M.L.; Chen, I.M.; Head, D.R.; Appelbaum, F.R.; Willman, C.L. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cyto-genetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study. Blood 1997, 89 (9), 3323-3329.

Mrozek, K.; Heinonen, K.; Lawrence, D.; Carroll, A.J.; Koduru, P.R.K.; Rao, K.W.; Strout, M.P.; Hutchison, R.E.; Moore, J.O.; Mayer, R.J.; Schiffer, C.A.; Bloomfield, C.D. Adult patients with de novo acute myelogenous leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B study. Blood 1997, 90 (11), 45324538.

List, A.F.; Kopecky, K.J.; Willman, C.L.; Head, D.R.; Persons, D.L.; Slovak, M.L.; Dorr, R.; Karanes, C.; Hynes,

H.E.; Doroshow, J.H.; Shurafa, M.; Appelbaum, F.R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Study Group study. Blood 2001, 98, 3212.

13. Mark, H.F.L. Bone Marrow Cytogenetics and Hematologic Malignancies. In The Cytogenetic Symposia; Kaplan, B.J., Dale, K.S., Eds.; Association of Cytogenetic Technologists: Burbank, CA, 1994.

14. Mark, H.F.L. Cytogenetic Aberrations in Hematologic Malignancies. In The Cytogenetic Symposia; Dunn, B., Ed.; Association of Cytogenetic Technologists: San Antonio, TX, 2004; in preparation/in press.

15. Nowell, P.C.; Hungerford, D.A. A minute chromosome in human chronic myelocytic leukemia (CML). Science 1960, 132, 1497.

16. Rowley, J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 234, 290293.

17. http://www.Vysis.com.

18. Anastasi, J.; Roulston, D. Myeloid Hematopoietic Disorders. In Medical Cytogenetics; Mark, H.F.L., Ed.; Marcel Dekker, Inc.: New York, 2000; 275-348.

19. Mark, H.F.L.; Jenkins, R.; Miller, W. Current applications of molecular cytogenetic technologies. Ann. Clin. Lab. Sci. 1996, 27, 47-56.

20. Mark, H.F.L.; Sikov, W.; Safran, H.; King, T.C.; Griffith, R.C. Fluorescent in situ hybridization for assessing the proportion of cells with trisomy 4 in a patient with acute non-lymphoblastic leukemia. Ann. Clin. Lab. Sci. 1995, 25, 330-335.

21. Mark, H.F.L.; Rehan, J.; Mark, S.; Santoro, K.; Zolnierz, K. FISH analysis of single-cell trisomies for determination of clonality. Cancer Genet. Cytogenet. 1998, 102, 1-5.

22. Mark, H.F.L. FISH as an Adjunct to Conventional Cytogenetics: Analysis of Metaphase and Interphase Cells. In Advances in Structural Biology; Malhotra, S., Ed.; Jai Press, Inc.: Stamford, CT, 2000; Vol. 6, 1 -39.

23. Miranda, R.N.; Mark, H.F.L.; Medeiros, L.J. Fluorescent in situ hybridization in routinely processed bone marrow aspirate clot and core biopsy sections. Am. J. Pathol. 1994, 145 (6), 1-6.

24. Sokolic, R.A.; Ferguson, W.; Mark, H.F.L. Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome. Cancer Genet. Cytogenet. 1999, 115, 106-113.

25. Blancato, J.K.; Haddad, B.R. Fluorescent in situ Hybridization (FISH): Principles and Methodology. In Medical Cytogenetics; Mark, H.F.L., Ed.; Marcel Dekker, Inc.: New York, 2000; 141-164.

26. Mark, H.F.L. Fluorescent in situ Hybridization (FISH): Applications for Clinical Cytogenetics Laboratories. In Medical Cytogenetics; Mark, H.F.L., Ed.; Marcel Dekker, Inc.: New York, 2000; 553-578.

27. Mark, H.F.L. Medical Cytogenetics; Marcel Dekker, Inc.: New York, 2000.

28. Estalilla, O.; Rintels, P.; Mark, H.F.L. Trisomy 10 in leukemia. Cancer Genet. Cytogenet. 1998, 101, 68-71.

29. Mark, H.F.L.; Mark, Y.; Sotomayor, E.; Sambandam, S. A patient with myelodysplastic syndrome studied by GTG-banding and fluorescent in situ hybridization. Cytobios 1998, 94, 121-128.

30. Mark, H.F.L.; Gray, Y.; Khorsand, J.; Mark, Y.; Sikov, W. A multimodal approach in diagnosing patients with hematopoietic disorders. Cancer Genet. Cytogenet. 1999, 109, 14-20.

31. Mark, H.F.L.; Pryzgoda, J.; Sikov, W. Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens. Pathobiology 1998, 66, 216-220.

32. Fourth International Workshop on Chromosomes in Leukemia. A prospective study of acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 1984, 11, 249-360.

33. Arif, M.; Tanaka, K.; Damodaran, C.; Asou, H.; Kyo, T.; Dohy, H.; Kamada, N. Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization. Leuk. Res. 1996, 20 (9), 709-716.

34. Bloomfield, C.D.; Lawrence, D.; Byrd, J.C.; Carroll, A.; Pettenati, M.J.; Tantravahi, R.; Patil, S.R.; Davey, F.R.; Berg, D.T.; Schiffer, C.A.; Arthur, D.C.; Mayer, R.J. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998, 58 (18), 41734179.

35. Estey, E.H. Therapeutic options for acute myelogenous leukemia. Cancer 2001, 92 (5), 1059-1073.

36. Kibbelaar, R.E.; Mulder, J.W.R.; Dreef, E.J.; van Kamp, H.; Fibbe, W.E.; Wessels, J.W.; Beverstock, G.C.; Haak, H.L.; Khan, P.M. Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: A comparison of banding and fluorescence in situ hybridization. Blood 1993, 82 (3), 904-913.

37. Wyandt, H.E.; Chinnappan, D.; Ioannidou, S.; Salama, M.; O'Hara, C. Fluorescence in situ hybridization to assess aneuploidy for chromosomes 7 and 8 in hematologic disorders. Cancer Genet. Cytogenet. 1998, 102, 114124.

38. Campana, D.; Piu, C.-H. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 1995, 85 (6), 1416-1434.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment